Kairos Pharma, LTD.

Kairos Pharma, Ltd. is a U.S.-based clinical-stage pharmaceutical company focused on acquiring, licensing, and developing drug candidates and related intellectual property. The company has no approved products or product sales yet, and its current business is centered on preclinical and clinical development, IP portfolio building, and capital raising to fund operations.

27.07

27.07

— Kairos Pharma, LTD.
%
Licensed therapeutic programs0% Exclusive license rights to patented technologies and drug-development programs sourced from Cedars.
Preclinical development45% Early-stage research, candidate selection, and nonclinical studies to advance product concepts.
Clinical development35% Human clinical studies and related regulatory preparation for product candidates.
Intellectual property and business development20% Patent portfolio management, licensing, and partnering activities that support commercialization.

Kairos Pharma does not yet sell approved products, so its near-term counterparties are not traditional end customers...

  • Equity investorsprimary

    Provide capital through IPO, PIPE, ELOC, and private financings because the company has no product revenue.

  • Technology licensorsprimary

    Supply exclusive patent rights and know-how, including Cedars-licensed programs that underpin the pipeline.

  • Strategic advisors and consultantssecondary

    Support corporate strategy, investor relations, valuation, and financing execution.

  • Potential pharmaceutical partnerssecondary

    May license or co-develop programs to help fund development and future commercialization.

  • Future healthcare end usersemerging

    Hospitals, physicians, and patients would be the ultimate users if candidates are approved.

Kairos Pharma is headquartered in the United States and its current operating footprint is primarily U.S...

  • •Headquartered in the United States
  • •Operations are centered on U.S. clinical and corporate activities
  • •Uses Canadian advisory services for investor communications
  • •Uses Puerto Rico-based consulting for capital markets support
  • •No disclosed country revenue because product sales have not started

Kairos Pharma’s strategy is to advance licensed therapeutic programs through preclinical and clinical development while...

01
Advance pipeline programsmedium-term

Clinical progress is the main value driver for a company with no product sales.

02
Secure fundingshort-term

The company needs external capital to fund operations until any product revenue exists.

03
Pursue partnering and licensingmedium-term

Collaborations can provide cash, validation, and commercialization reach without full internal buildout.

04
Strengthen market positioningshort-term

Investor communications and corporate strategy support access to capital and deal flow.

Kairos Pharma is exposed to the core risks of a clinical-stage biotech: it may never obtain regulatory approval, may...

critical

Funding shortfall

The company has no sales and must finance development through equity, debt, or partnerships.

Scope
Operations, clinical trials, and commercialization readiness
Materiality
high
critical

Clinical and regulatory failure

Drug candidates may not demonstrate safety or efficacy, or may not obtain approval.

Scope
Pipeline programs and future revenue potential
Materiality
high
high

Shareholder dilution

Recent and future financings, including PIPEs and ELOC usage, can expand share count materially.

Scope
Existing common stockholders
Materiality
high
high

Going-concern pressure

Persistent losses and negative operating cash flow increase the risk of liquidity stress.

Scope
Balance sheet and operating continuity
Materiality
high
medium

Dependence on licensors and third parties

The company relies on licensed IP, advisors, and outside service providers to progress programs.

Scope
Program continuity and deal terms
Materiality
medium
Revenue recognition
Any future collaboration or license revenue may be recognized over time or at milestones depending on contract terms
Stock-based compensation
Can materially increase G&A expense without cash outflow
Warrants and equity financing costs
Affects dilution, financing expense, and potentially fair value measurements
Going-concern and liquidity estimates
Management judgment affects disclosures and assessment of funding sufficiency

Keros Therapeutics, Inc.

KROS · Pharmaceutical Preparations

CERO THERAPEUTICS HOLDINGS, INC.

CERO · Biological Products, (No Diagnostic Substances)

Kalaris Therapeutics, Inc.

KLRS · Biological Products, (No Diagnostic Substances)

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

Karyopharm Therapeutics Inc.

KPTI · Pharmaceutical Preparations

Cadrenal Therapeutics, Inc.

CVKD · Pharmaceutical Preparations

: 28/04/2026